These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 34546308)

  • 1. Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases.
    Serkland TT; Skrede S; Berg JA
    JAMA; 2021 Sep; 326(11):1068-1069. PubMed ID: 34546308
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases.
    Le Tilly O; Paintaud G; Ternant D
    JAMA; 2021 Sep; 326(11):1069. PubMed ID: 34546307
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases.
    Papamichael K; Dubinsky MC; Cheifetz AS
    JAMA; 2021 Sep; 326(11):1067. PubMed ID: 34546306
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases.
    Vande Casteele N
    JAMA; 2022 Apr; 327(15):1506. PubMed ID: 35438733
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases-Reply.
    Syversen SW; Jahnsen J; Haavardsholm EA
    JAMA; 2022 Apr; 327(15):1506-1507. PubMed ID: 35438729
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases.
    Javor E; Hauser G; Skelin M
    JAMA; 2022 Apr; 327(15):1505-1506. PubMed ID: 35438732
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases-Reply.
    Syversen SW; Bolstad N; Haavardsholm EA
    JAMA; 2021 Sep; 326(11):1069-1070. PubMed ID: 34546304
    [No Abstract]   [Full Text] [Related]  

  • 8. [Usefulness of therapeutic monitoring of infliximab in the treatment of inflammatory bowel disease].
    Quera R; Moreno M; Simian D; Ibáñez P; Lubascher J; Figueroa C; Flores L; Kronberg U; Pizarro G; Fluxá D
    Rev Med Chil; 2018 Nov; 146(11):1241-1251. PubMed ID: 30725037
    [No Abstract]   [Full Text] [Related]  

  • 9. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases.
    Ungar B; Glidai Y; Yavzori M; Picard O; Fudim E; Lahad A; Haberman Y; Shouval DS; Weintraub I; Eliakim R; Ben-Horin S; Weiss B
    J Pediatr Gastroenterol Nutr; 2018 Oct; 67(4):507-512. PubMed ID: 29901557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is the Combination of Pharmacokinetic and Pharmacodynamic Monitoring of Infliximab-Treated Patients the Way Forward?
    Queiroz NSF; Charabaty A
    Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2631-2632. PubMed ID: 32092397
    [No Abstract]   [Full Text] [Related]  

  • 11. Usefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease.
    Gil Candel M; Gascón Cánovas JJ; Urbieta Sanz E; Gómez Espín R; Nicolás de Prado I; Iniesta Navalón C
    Rev Esp Enferm Dig; 2020 May; 112(5):360-366. PubMed ID: 32338010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing biological therapy in Crohn's disease.
    Gecse KB; Végh Z; Lakatos PL
    Expert Rev Gastroenterol Hepatol; 2016; 10(1):37-45. PubMed ID: 26471077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease.
    Bodini G; Giannini EG; Savarino V; Del Nero L; Lo Pumo S; Brunacci M; De Bortoli N; Jain A; Tolone S; Savarino E
    Dig Liver Dis; 2018 May; 50(5):452-456. PubMed ID: 29274766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated With Infliximab.
    Barberio B; D'Incà R; Facchin S; Dalla Gasperina M; Fohom Tagne CA; Cardin R; Ghisa M; Lorenzon G; Marinelli C; Savarino EV; Zingone F
    Inflamm Bowel Dis; 2020 Apr; 26(5):756-763. PubMed ID: 31504536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Drug Monitoring-guided High-dose Infliximab for Infantile-onset Inflammatory Bowel Disease: A Case Series.
    Assa A; Dorfman L; Shouval DS; Shamir R; Cohen S
    J Pediatr Gastroenterol Nutr; 2020 Oct; 71(4):516-520. PubMed ID: 32639454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
    Holmstrøm RB; Mogensen DV; Brynskov J; Ainsworth MA; Nersting J; Schmiegelow K; Steenholdt C
    Dig Dis Sci; 2018 Jun; 63(6):1583-1591. PubMed ID: 29564674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD.
    Lega S; Phan BL; Rosenthal CJ; Gordon J; Haddad N; Pittman N; Benkov KJ; Dubinsky MC
    Inflamm Bowel Dis; 2019 Jan; 25(1):134-141. PubMed ID: 29868777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn's Disease.
    Hirten R; Longman RS; Bosworth BP; Steinlauf A; Scherl E
    Am J Gastroenterol; 2015 Dec; 110(12):1737-8. PubMed ID: 26673509
    [No Abstract]   [Full Text] [Related]  

  • 19. An Erythematous papular eruption in a woman with Crohn disease treated with infliximab.
    Howard HE; Zwerner JP; Byers J; Tkaczyk E
    Dermatol Online J; 2016 Oct; 22(10):. PubMed ID: 28329591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De-escalation of Infliximab Maintenance Therapy from 8- to 10-week Dosing Interval Based on Faecal Calprotectin in Patients with Crohn's Disease.
    Papamichael K; Karatzas P; Mantzaris GJ
    J Crohns Colitis; 2016 Mar; 10(3):371-2. PubMed ID: 26546496
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.